BRAF and neoplasm: In the BRAF mutant model, the combination resulted in tumor regressions at Day 19 with tumor volumes that were lower than those achieved with either drug alone (Figure 2A, p-value = 0.008 for the comparison of the combination to either AZD8055 or selumetinib alone).